Afinitor® in patients with non-cancerous tumours

Data published in The Lancet has shown that patients on Afinitor® (everolimus) tablets with non-cancerous kidney tumours known as renal angiomyolipomas associated with tuberous sclerosis complex (TSC) experienced a significant reduction in tumour size and the absence of tumour progression
Source: Pharmacy Europe - Category: Drugs & Pharmacology Source Type: news